G A McArthur1, M Maio2, A Arance3, P Nathan4, C Blank5, M-F Avril6, C Garbe7, A Hauschild8, D Schadendorf9, O Hamid10, M Fluck11, M Thebeau12, J Schachter13, R Kefford14, M Chamberlain15, M Makrutzki16, S Robson16, R Gonzalez17, K Margolin18. 1. Department of Medical Oncology, Peter MacCallum Cancer Centre, East Melbourne and University of Melbourne, Parkville, Australia. 2. AOU Senese Policlinico Santa Maria Alle Scotte, Siena, Italy. 3. Department of Medical Oncology, Hospital Clínic Barcelona, Spain. 4. Mount Vernon Hospital, Centre for Cancer Treatment, Northwood, UK. 5. The Netherlands Cancer Institute, Amsterdam, The Netherlands. 6. University Paris Descartes, Hospital Cochin, APHP, Paris, France. 7. Department of Dermatology, University Hospital Tuebingen, Tuebingen. 8. Department of Dermatology, University Hospital Schleswig-Holstein (UKSH), Campus Kiel, Kiel. 9. Department of Dermatology, Comprehensive Cancer Center, University Hospital Essen, Essen, Germany. 10. Angeles Clinic and Research Institute, Los Angeles, USA. 11. Fachklinik Hornheide, Munster, Germany. 12. Moffitt Cancer Center, Tampa, USA. 13. Chaim Sheba Medical Centre, Oncology Institute, Ramat-Gan, Israel. 14. Crown Princess Cancer Centre Westmead Hospital and Department of Clinical Medicine, Macquarie University, Sydney NSW, Australia. 15. Seattle Cancer Care Alliance, Seattle, USA. 16. F. Hoffmann-La Roche Ltd, Basel, Switzerland. 17. University of Colorado Cancer Center, Aurora. 18. City of Hope, Duarte, USA.
Abstract
Background: Vemurafenib has shown activity in patients with BRAFV600 mutated melanoma with brain metastases (BM). This phase 2 study evaluated vemurafenib in patients with/without prior treatment for BM. Methods: Patients with BRAFV600 mutated melanoma with BM were enrolled into cohort 1 (previously untreated BM) and cohort 2 (previously treated BM) and received vemurafenib (960 mg BID) until disease progression (PD) or intolerance. Primary endpoint was best overall response rate (BORR) in the brain in cohort 1 that was evaluated using modified RECIST 1.1 criteria using lesions ≥0.5 cm to assess response. Results: 146 patients were treated (cohort 1 n = 90; cohort 2 n = 56), 62% of whom were male. Median (range) time since diagnosis of BM: 1.0 (0-9) month in cohort 1 and 4.2 (1-68) months in cohort 2. Median duration of treatment was 4.1 months (range 0.3-34.5) in cohort 1 and 4.1 months (range 0.2-27.6) in cohort 2. Intracranial BORR in cohort 1 by an independent review committee (IRC) was 18% (2 CRs, 14 PRs). Extracranial BORR by IRC was 33% in cohort 1 and 23% in cohort 2. Median PFS (brain only, investigator-assessed) was 3.7 months (range 0.03-33.4; IQR 1.9-5.6) in cohort 1 and 4.0 months (range 0.3-27.4; IQR 2.2-7.4) in cohort 2. Median OS was 8.9 months (range 0.6-34.5; IQR 4.9-17.0) in cohort 1 and 9.6 months (range 0.7-34.3; IQR 4.5-18.4) in cohort 2. Adverse events (AEs) were similar in type, grade and frequency to other studies of single-agent vemurafenib. Grade 3/4 AEs occurred in 59 (66%) patients in cohort 1 and 36 (64%) in cohort 2. Overall, 84% of patients died during the study (86% in cohort 1 and 80% in cohort 2), mainly due to disease progression. Conclusions: The study demonstrates clinically meaningful response rates of melanoma BM to vemurafenib, which was well tolerated and without significant CNS toxicity.
Background: Vemurafenib has shown activity in patients with BRAFV600 mutated melanoma with brain metastases (BM). This phase 2 study evaluated vemurafenib in patients with/without prior treatment for BM. Methods:Patients with BRAFV600 mutated melanoma with BM were enrolled into cohort 1 (previously untreated BM) and cohort 2 (previously treated BM) and received vemurafenib (960 mg BID) until disease progression (PD) or intolerance. Primary endpoint was best overall response rate (BORR) in the brain in cohort 1 that was evaluated using modified RECIST 1.1 criteria using lesions ≥0.5 cm to assess response. Results: 146 patients were treated (cohort 1 n = 90; cohort 2 n = 56), 62% of whom were male. Median (range) time since diagnosis of BM: 1.0 (0-9) month in cohort 1 and 4.2 (1-68) months in cohort 2. Median duration of treatment was 4.1 months (range 0.3-34.5) in cohort 1 and 4.1 months (range 0.2-27.6) in cohort 2. Intracranial BORR in cohort 1 by an independent review committee (IRC) was 18% (2 CRs, 14 PRs). Extracranial BORR by IRC was 33% in cohort 1 and 23% in cohort 2. Median PFS (brain only, investigator-assessed) was 3.7 months (range 0.03-33.4; IQR 1.9-5.6) in cohort 1 and 4.0 months (range 0.3-27.4; IQR 2.2-7.4) in cohort 2. Median OS was 8.9 months (range 0.6-34.5; IQR 4.9-17.0) in cohort 1 and 9.6 months (range 0.7-34.3; IQR 4.5-18.4) in cohort 2. Adverse events (AEs) were similar in type, grade and frequency to other studies of single-agent vemurafenib. Grade 3/4 AEs occurred in 59 (66%) patients in cohort 1 and 36 (64%) in cohort 2. Overall, 84% of patients died during the study (86% in cohort 1 and 80% in cohort 2), mainly due to disease progression. Conclusions: The study demonstrates clinically meaningful response rates of melanoma BM to vemurafenib, which was well tolerated and without significant CNS toxicity.
Authors: Ethan S Srinivasan; Aaron C Tan; Carey K Anders; Ann Marie Pendergast; Dorothy A Sipkins; David M Ashley; Peter E Fecci; Mustafa Khasraw Journal: Mol Cancer Ther Date: 2021-01-05 Impact factor: 6.261
Authors: Hani M Babiker; Sara A Byron; William P D Hendricks; William F Elmquist; Gautham Gampa; Jessica Vondrak; Jessica Aldrich; Lori Cuyugan; Jonathan Adkins; Valerie De Luca; Raoul Tibes; Mitesh J Borad; Katie Marceau; Thomas J Myers; Linda J Paradiso; Winnie S Liang; Ronald L Korn; Derek Cridebring; Daniel D Von Hoff; John D Carpten; David W Craig; Jeffrey M Trent; Michael S Gordon Journal: Invest New Drugs Date: 2018-09-28 Impact factor: 3.850
Authors: Paul D Brown; Manmeet S Ahluwalia; Osaama H Khan; Anthony L Asher; Jeffrey S Wefel; Vinai Gondi Journal: J Clin Oncol Date: 2017-12-22 Impact factor: 44.544
Authors: Daniel A Pomeranz Krummel; Tahseen H Nasti; Milota Kaluzova; Laura Kallay; Debanjan Bhattacharya; Johannes C Melms; Benjamin Izar; Maxwell Xu; Andre Burnham; Taukir Ahmed; Guanguan Li; David Lawson; Jeanne Kowalski; Yichun Cao; Jeffrey M Switchenko; Dan Ionascu; James M Cook; Mario Medvedovic; Andrew Jenkins; Mohammad K Khan; Soma Sengupta Journal: Int J Radiat Oncol Biol Phys Date: 2020-10-24 Impact factor: 7.038